Adverse events following Haemophilus influenzae type b vaccines in the Vaccine Adverse Event Reporting System, 1990-2013

J Pediatr. 2015 Apr;166(4):992-7. doi: 10.1016/j.jpeds.2014.12.014. Epub 2015 Jan 15.

Abstract

Objective: To characterize adverse events (AEs) after Haemophilus influenzae type b (Hib) vaccines reported to the US Vaccine Adverse Event Reporting System (VAERS), a spontaneous reporting surveillance system.

Study design: We searched VAERS for US reports after Hib vaccines among reports received from January 1, 1990, to December 1, 2013. We reviewed a random sample of reports and accompanying medical records for reports classified as serious. All reports of death were reviewed. Physicians assigned a primary clinical category to each reviewed report. We used empirical Bayesian data mining to identify AEs that were disproportionally reported after Hib vaccines.

Results: VAERS received 29,747 reports after Hib vaccines; 5179 (17%) were serious, including 896 reports of deaths. Median age was 6 months (range 0-1022 months). Sudden infant death syndrome was the stated cause of death in 384 (51%) of 749 death reports with autopsy/death certificate records. The most common nondeath serious AE categories were neurologic (80; 37%), other noninfectious (46; 22%) (comprising mainly constitutional signs and symptoms); and gastrointestinal (39; 18%) conditions. No new safety concerns were identified after clinical review of reports of AEs that exceeded the data mining statistical threshold.

Conclusion: Review of VAERS reports did not identify any new or unexpected safety concerns for Hib vaccines.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adverse Drug Reaction Reporting Systems / statistics & numerical data*
  • Bacterial Capsules
  • Bayes Theorem
  • Child
  • Child, Preschool
  • Female
  • Follow-Up Studies
  • Haemophilus Infections / mortality
  • Haemophilus Infections / prevention & control*
  • Haemophilus Vaccines / adverse effects*
  • Haemophilus influenzae type b / immunology*
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Retrospective Studies
  • Risk Assessment / methods*
  • Survival Rate / trends
  • United States / epidemiology

Substances

  • Haemophilus Vaccines
  • Haemophilus influenzae type b polysaccharide vaccine